Atara Biotherapeutics Inc | Needs refresh | Last updated: 2026-04-23T10:26:17Z
Atara Biotherapeutics Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for ATA3219 (Phase 1).
| Asset | Indication | Modality | Stage | Public Note |
|---|---|---|---|---|
| Related Documents | n/a | n/a | n/a | Public pipeline row |
| ATA3219 | n/a | n/a | Phase 1 | Public pipeline row |
| ATA3431 | B-Cell Malignancies | n/a | n/a | Public pipeline row |
| Tolerability | n/a | n/a | n/a | Public pipeline row |
| Flexible delivery. Biologics-like costs. | n/a | n/a | Preclinical | Public pipeline row |
| Big vision. Bigger impact. | n/a | n/a | n/a | Public pipeline row |
| ATA188 | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | n/a | Phase 1 | Phase 2 | Public pipeline row |
Estimated cash runway: Unknown.
This is an automated estimate and may differ from company guidance.
| NCT ID | Phase | Status | Enrollment | Primary Completion |
|---|---|---|---|---|
| NCT03283826 | Phase 1 | Phase 2 | TERMINATED | 134 | 2023-11-09 |
Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.
Get the weekly biotech catalyst watchlistThis page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.